Epizyme Inc
F:EPE
Fundamental Analysis
Significant reliance on Tazemetostat exposes Epizyme to concentrated revenue risk, and any clinical or regulatory setbacks for this lead asset could materially reduce the firm’s prospects.
Tazemetostat’s successful initial approvals for advanced epithelioid sarcoma and certain follicular lymphoma settings could open the door to broader label expansions and make Epizyme an important player in epigenetic oncology.

Revenue & Expenses Breakdown
Epizyme Inc
Balance Sheet Decomposition
Epizyme Inc
Current Assets | 186.8m |
Cash & Short-Term Investments | 144.4m |
Receivables | 11.2m |
Other Current Assets | 31.2m |
Non-Current Assets | 77.3m |
PP&E | 19.2m |
Intangibles | 40.8m |
Other Non-Current Assets | 17.4m |
Free Cash Flow Analysis
Epizyme Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Epizyme Inc
Revenue
|
53m
USD
|
Cost of Revenue
|
-13m
USD
|
Gross Profit
|
40.1m
USD
|
Operating Expenses
|
-236.2m
USD
|
Operating Income
|
-196.2m
USD
|
Other Expenses
|
-11.6m
USD
|
Net Income
|
-207.7m
USD
|
EPE Profitability Score
Profitability Due Diligence
Epizyme Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Epizyme Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
EPE Solvency Score
Solvency Due Diligence
Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPE Price Targets Summary
Epizyme Inc
Dividends
Current shareholder yield for EPE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?